PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



Dr. Morepen CBI .pdf


Original filename: Dr. Morepen CBI.pdf
Title: Morepen Laboratories Scores No. 1 Position Globally for its Bulk Drug Montelukast

This PDF 1.4 document has been generated by wkhtmltopdf 0.12.3 / Qt 4.8.7, and has been sent on pdf-archive.com on 27/01/2017 at 08:41, from IP address 112.196.x.x. The current document download page has been viewed 287 times.
File size: 225 KB (4 pages).
Privacy: public file




Download original PDF file









Document preview


Morepen
Laboratories Scores No. 1 Position Globally for its Bulk
X
Drug Montelukast
Business Wire | Mumbai |


Morepen Laboratories Scores No. 1 Position Globally for its Bulk Drug Montelukast

 

    
A+ a-     0
Business Wire India
Morepen Laboratories Ltd. has established a leadership position for its anti-asthmatic bulk drug Montelukast in the global
market. As per the latest report published by a global research firm - QYR Research, Morepen is the No.1 supplier globally in
terms of total quantity sold, followed by Mylan and TAPI (Teva) who appear on the second and third position respectively.
Morepen’s global sales for Montelukast Sodium stood at 16240 kgs in the calender year 2015, resulting in a market share of 23
per cent (approx.) compared to Mylan’s and Teva’s 12 per cent each, the report claims.

This was disclosed by Mr. Sushil Suri, Chairman and Managing Director, Morepen
Laboratories Ltd. after the company’s board meeting, which discussed and took
on record the fourth quarter and annual results of the company for the financial
year 2015-16. “After attaining leadership in Loratadine, by being world’s largest
generic supplier of the bulk drug, Morepen Laboratories Ltd. has attained a
leadership in its second molecule -Montelukast,” he pointed out.
Morepen Laboratories Ltd. has reported an over 25-fold increase in its net profit
for the financial year ended March 31, 2016. The net profit increased from Rs. 58
lakhs in FY 2014 -15 to Rs. 15.78 crore in FY 2015-16. The total operating revenue
in FY 2015-16 stood at Rs. 452.46 crore as against Rs. 370.26 crore in the
previous fiscal, registering a growth of 22.20 per cent.
For the fourth quarter ended March 31, 2016, net profit rose to Rs. 2.77 crore on a
total operating revenue of Rs. 123.59 crore as compared to a loss of Rs. 3.72
crore on a total operating revenue of Rs. 85.36 crore in the corresponding quarter
of the previous fiscal.
Morepen’s EBIDTA increased by 36.30 per cent in fiscal 2015-16 at Rs. 65.38 crore and the cash surplus (i.e. EBDTA) rose by 40
per cent at Rs. 54.96 crore compared to Rs. 47.95 crore and Rs. 39.31 crore respectively, in the previous fiscal.
“Enhanced focus on cost reduction and adoption of innovative processes resulted in this remarkable turnaround, putting the
company back on the profit trajectory,” Mr. Suri said.
Q4 marked excellent performance in all business segments particularly bulk drugs (API) which has grown by more than 50%,
while Home Diagnostics and Finished Dosages segments also outperformed and registered a remarkable growth of 35% and
40% respectively adding to the outstanding quarterly performance.
Total revenues from the bulk drug Montelukast in Q4 grew by more than 90% at Rs. 25.71 crore. Thus, Montelukast registered
the highest growth amongst bulk drugs followed by Loratadine and Atorvastatin, which grew by 20% and 37% respectively, over
Q4 last year. In the FY 2015-16, total revenue from Montelukast crossed Rs. 74 crores and is likely to cross Rs. 100 crore mark
in fiscal 2016-17.
Exports: With strategic international positioning, the company’s export turnover has crossed Rs. 200 crores in FY 2015-16,
registering a growth of 32 per cent. The exports turnover is expected to grow by 25% Year-on-Year and is likely to cross Rs. 250
crore in fiscal 2016-17.
In the home health category, Morepen’s Diagnostics division grew by 23% Year-on-year. The company cemented its leadership
in Blood Glucose Monitors market by registering 41% growth in fiscal 2015-16 with a top line of Rs.33.38 crores. It sold more
than 30 million test strips in fiscal 2015-16. Looking at increasing incidence of diabetic cases in India, this segment offers great
opportunity for growth in the coming years.
About Morepen Laboratories Ltd.

Morepen Laboratories Ltd. is a 30-year old pharmaceutical and healthcare products company. The company went public in the
year 1993 and is currently listed at both the Bombay Stock Exchange as well as the National Stock Exchange.
Morepen is engaged in the manufacturing and sale of APIs/ Bulk Drugs, Home Diagnostics, Formulations and OTC products.
The company’s state-of-the-art manufacturing facility at Baddi (Himachal Pradesh) comprises a scientifically integrated
complex of 10 plants, each with a specific product profile. The USFDA approved plant at Masulkhana is for manufacture of
Loratadine, an anti-allergy drug – internationally known as Claritin. The new blockbuster drug Montelukast is also manufactured
at this FDA approved site. The large and spread out manufacturing facility at Baddi manufactures latest and much in demand
products like Atorvastatin, Rosuvastatin, Sitagliptin and others for regulated markets of USA and also for non-regulated markets
across the globe.
Morepen markets over 100 branded formulations under six major therapeutic segments in the domestic market. It has WHO
GMP facilities for manufacturing of Formulations. The company’s manufacturing facilities are backed by a strong dedicated
team of research and development (R&D) professionals who ensure stringent quality standards. In Home - Diagnostics
business, Morepen has a formidable presence in Blood Glucose Monitors and Blood Pressure Monitors, which are imported by
the company for sale in the domestic market. The company’s OTC brands are being promoted under its wholly owned
subsidiary Dr. Morepen Limited. Dr. Morepen’s famous OTC product line, including Burnol, Lemolate, Sat-Isabgol, Fever-X, PainX and others, has a significant presence in the domestic market.
Photo Caption: Mr. Sushil Suri, Chairman and Managing Director, Morepen Laboratories Ltd
Tags Business/ Finance

Advertising

PR & marketing

Advertisements

FREE Demat A/c + Rs.2000 Cashback ...Click here
Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
Get the most detailed result analysis on the web - Real Fast!
Actionable & Award-Winning Research on 500 Listed Indian Companies.

Comments

 Login



There are no comments to display. Be the first one to comment!

Industry Newsletter



Pharmaceuticals Newsletter - January 16 to 20, 2017
Oil and Gas Newsletter - January 16 to 20, 2017
Metal and Mining Newsletter - January 16 to 20, 2017
Merger and Acquisition Newsletter - January 16 to 20, 2017
Telecom Newsletter - January 16 to 20, 2017
Information Technology Newsletter - January 16 to 20, 2017
Retail Newsletter - January 16 to 20, 2017
Real Estate Newsletter - January 16 to 20, 2017
Infrastructure Newsletter - January 16 to 20, 2017
Hotel and Tourism Newsletter - January 16 to 20, 2017
More 

facebook | twitter

CONNECT WITH IIFL:

Commodity Ideas Stock Ideas
IIFL Live Corporate News
 RSS

 CUSTOMER CARE
Technology/Trader Terminal related queries

022-41514151
Equity/Currency & Commodity/Spot

022-40071000
Gold/NCD/NBFC/Insurance and NPS

180030001155 / 022-61064444

Login To Trade | Open a Trading Account

Investor Relations | About IIFL | We're Hiring | Contact Us

Friday, 27 January 2017 11:13 IST
IIFL GROUP
Trade

Premia

Wealth

Flame

Property Solutions

Business Partners

Finance

PRODUCTS & SERVICES
Desktop Widget

Research

Mortgages

Insurance

Wealth Management

Discretionary
PMS

TT
Edge

Business loans
Personal Loan

TRADING DOCUMENTATION
Download TT

TT Login

TT Demo

Account Details

Fund Transfer

Helpdesk

Download Forms

Document &
Info

USEFUL LINKS
BSE

NSE

MCX

NCDEX

Bullion Desk

Forex Factory

Exchange
Holidays

OFFBEAT
Bschool

Economy

CALCULATORS

Lifestyle

RBI
Governors

Finance Ministers

Prime Ministers

Famous Speeches

Income Tax

Home Loan EMI

Gold Loan calculator

Auto Loan EMI

Revolving credit interest
calculator

Education Loan EMI

HRA Exemption

Retirement
Planning

Savings
Estimator

EMI
Calculator

GLOSSARY:
Accountancy Advertising Budget Commerce Derivatives Economics Finance General Mgmt. HR Mgmt. IT
Marketing Material Mgmt.

STOCKS:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

MUTUAL FUNDS:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

INSURANCE:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Disclaimer
Policy

Disclaimer - Research Disclaimer

Discussion Boards

Disclaimer - Twitter

Terms & Conditions

Privacy

ATTENTION INVESTORS:
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and
real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders,
entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia,
corporates and investors among others.
Copyright © 2017 India Infoline Ltd. All rights Reserved.
National Stock Exchange of India Ltd. SEBI Regn. No. : INB231097537/ INF231097537/ INE231097537,
Bombay Stock Exchange Ltd. SEBI Regn. No.:INB011097533/ INF011097533/ BSE Currency,
MCX Stock Exchange Ltd. SEBI Regn. No.: INB261097530/ INF261097530/ INE261097537,
United Stock Exchange Ltd. SEBI Regn. No.: INE271097532
web8


Dr. Morepen CBI.pdf - page 1/4
Dr. Morepen CBI.pdf - page 2/4
Dr. Morepen CBI.pdf - page 3/4
Dr. Morepen CBI.pdf - page 4/4

Related documents


dr morepen cbi
sushil suri cbi
morepen sushil suri
dr morepen sushil suri cbi
sushil suri cbi
dr morepen sushil suri


Related keywords